Xenical Long-Term Switch Odds Carry More Weight, Experts Say
While long-term prospects for a Xenical switch are promising, it is unlikely that GlaxoSmithKline will receive a recommendation in favor of its Rx-to-OTC switch application for orlistat during an upcoming joint FDA advisory committee meeting, some experts in the field said
You may also be interested in...
GlaxoSmithKline's NDA for over-the-counter use of orlistat (tetrahydrolipstatin) will be reviewed at a joint meeting of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees on Jan. 23. Orlistat is marketed as the prescription weight-loss drug Xenical by Roche; GSK acquired nonprescription marketing rights to the drug in July 2004. GSK filed an NDA for the Rx-to-OTC switch in June. [Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
FDA's handling of Barr's application to switch Plan B over the counter could elicit heightened external scrutiny of the agency's ability to make drug approval decisions based solely on science and public health
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011